Oxytocin research - OXT-NEO
OXT-NEO is a product under development as part of a research programme dedicated to Prader‑Willi syndrome starting from the neonatal period.
The research work conducted is part of a scientific approach aimed at exploring the role of oxytocin in newborns and infants with Prader‑Willi syndrome on sucking and swallowing as well as social skills deficiencies.
This research is conducted with regulatory supervision and undergoes successive evaluations according to the requirements applicable to healthcare products under development.
OXT‑NEO does not have marketing authorisation for the Prader‑Willi syndrome indication.
Oxytocin
Oxytocin is produced naturally in the brain by the hypothalamus, and acts as both a hormone and a neuromodulator.
In scientific literature, oxytocin is described as being involved in social behaviours such as attachment and stress processes, as well as in feeding. In humans, development and maturation of the oxytocinergic system begin very soon after birth and are part of the early neurobiological development processes described in the first weeks of life.
A scientific research approach to Prader-Willi syndrome in neonates and infants with Prader Willi Syndrome
The activities described are part of a research program dedicated to studying the role of oxytocin in Prader‑Willi syndrome, from the first stages of neurobiological development.
This research program is based on data drawn from fundamental, pre-clinical and clinical research described in scientific literature, as well as on academic works conducted by several research teams.
The studies conducted aim to explore the characteristics of the study product and to assess its effects, particularly in terms of safety, efficacy and conditions for use, within a strictly regulated framework.
OXT‑NEO is currently in clinical development and does not have marketing authorisation for the Prader‑Willi syndrome indication.
